AMPA receptor (TARP γ8-dependent)

Class

small-molecule, potential first-in-class, TARPγ8-selective AMPA receptor negative allosteric modulator (NAM)

Pathway

selectively inhibits AMPA receptors that are co-assembled with the auxiliary protein TARP gamma-8 (TARPγ8), which is enriched in seizure-prone brain regions (hippocampus, neocortex) but has minimal expression in the hindbrain; intended to reduce excitatory glutamatergic neurotransmission at the seizure focus while avoiding the dose-limiting CNS tolerability effects of broader, non-selective AMPA receptor inhibition

AMPA receptors are ion channels activated by glutamate, the brain's primary excitatory neurotransmitter. When glutamate binds, these receptors open and allow charged ions to flow into neurons, producing fast excitatory signals that underlie normal brain communication. In conditions of excessive or poorly controlled excitation, such as epilepsy, this signaling becomes pathologically amplified, contributing to seizures. Directly blocking AMPA receptors can dampen this excess activity, but because AMPA receptors are expressed throughout the central nervous system, including brain regions that control movement, balance, and arousal, broad inhibition often produces sedation, dizziness, and coordination problems that limit how much drug can be used. AMPA receptors do not function alone; they associate with auxiliary proteins called TARPs (transmembrane AMPA receptor regulatory proteins), which vary in distribution across the brain. TARP gamma-8 is notably concentrated in the hippocampus and neocortex, regions strongly implicated in seizure generation, while being largely absent from the hindbrain structures responsible for basic motor and arousal functions. A compound designed to selectively inhibit only TARP gamma-8-associated AMPA receptors could, in principle, reduce excitatory drive at seizure-prone circuits while sparing receptor populations elsewhere, potentially improving tolerability relative to non-selective AMPA receptor blockade.